Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzzco1zUUN3ME2wMlAxPjZ7IN88US=> MYHTRW5ITVJ?
MV-4-11 M{TSOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEG1PFYh|ryP M4nscHNCVkeHUh?=
NKM-1 NHqySItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\0TWM2OD1yLkCxOlk6KM7:TR?= NELXNHdUSU6JRWK=
ML-2 NUnjeFd1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmr3TWM2OD1yLkCxPVg{KM7:TR?= MVTTRW5ITVJ?
BV-173 MkDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTBwMEKzNVQh|ryP Ml\xV2FPT0WU
RS4-11 NXHjToM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnSUlVOUUN3ME2wMlAzPTh5IN88US=> NGPRRm9USU6JRWK=
HL-60 M3;pVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\XXGpKSzVyPUCuNFI6ODhizszN NHnSWY1USU6JRWK=
KY821 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrVZpVKSzVyPUCuNFI6PzVizszN MnrsV2FPT0WU
ECC10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HWbGlEPTB;MD6wN|c6OiEQvF2= MYfTRW5ITVJ?
NCI-H720 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4ruV2lEPTB;MD6wOFAyOSEQvF2= MlHiV2FPT0WU
QIMR-WIL MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MljOTWM2OD1yLkC0Nlg4KM7:TR?= MXfTRW5ITVJ?
KG-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELCNYxKSzVyPUCuNFQ1QDZizszN Mnv0V2FPT0WU
TGW MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHIRYREUUN3ME2wMlA1PjN|IN88US=> MX7TRW5ITVJ?
ATN-1 NX2w[JVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XxNGlEPTB;MD6wOFc{OyEQvF2= Ml;mV2FPT0WU
RH-18 M{nqXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDiWoRiUUN3ME2wMlA3ODR6IN88US=> M37BcHNCVkeHUh?=
EW-18 M3jid2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPsTWM2OD1yLkC2PFQyKM7:TR?= M1jORnNCVkeHUh?=
NB17 M1\sfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHKO4VKSzVyPUCuNFcyOjRizszN MXLTRW5ITVJ?
SK-NEP-1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwMEeyNVMh|ryP M1zHXHNCVkeHUh?=
P12-ICHIKAWA NFjKbJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjqTWM2OD1yLkC3O|c5KM7:TR?= MYHTRW5ITVJ?
KARPAS-45 NEn3S3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zxbmlEPTB;MD6wO|gyPSEQvF2= MUDTRW5ITVJ?
EW-3 NGHjdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7GdoVIUUN3ME2wMlA5ODV|IN88US=> NGnhPItUSU6JRWK=
NB13 NH3Vc|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMEiyNFMh|ryP NYHrVoFrW0GQR1XS
NCI-H209 MoPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDJO401UUN3ME2wMlA5PzB2IN88US=> NGL4UGtUSU6JRWK=
NCI-H1092 NULoUmZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKwTWM2OD1yLkGwNlc2KM7:TR?= Mnu5V2FPT0WU
NH-12 NGDUTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3LTWM2OD1yLkGwO|Q1KM7:TR?= NETEdGtUSU6JRWK=
697 M3O2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jETmlEPTB;MD6xNFg{QSEQvF2= M1zUfXNCVkeHUh?=
KE-37 NIjvSIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vRXWlEPTB;MD6xNVM4KM7:TR?= MkXTV2FPT0WU
MOLT-4 M4ey[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMUWxOlkh|ryP M4rmOnNCVkeHUh?=
CHP-134 Ml3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMU[zNFYh|ryP MYfTRW5ITVJ?
D-283MED NYD4R5ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLXTWM2OD1yLkG3Olg3KM7:TR?= MUfTRW5ITVJ?
LU-135 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS5VpNKSzVyPUCuNVg2PTJizszN MmC3V2FPT0WU
LU-134-A Mn3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13oWGlEPTB;MD6xPFY4OSEQvF2= MmG1V2FPT0WU
EM-2 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMUm5NVgh|ryP NIWy[VZUSU6JRWK=
LU-139 M1Toc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHYdVNKSzVyPUCuNlA1QThizszN M1jNTXNCVkeHUh?=
ALL-PO NXj0XWUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXex[ohPUUN3ME2wMlIyQTh6IN88US=> NITYPZlUSU6JRWK=
NB12 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwMkOxNVUh|ryP NG\6boxUSU6JRWK=
KP-N-YN NH7uU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TFTGlEPTB;MD6yN|U4OyEQvF2= M37s[3NCVkeHUh?=
BEN Mlr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMkO5Olgh|ryP M4HxXnNCVkeHUh?=
HCC1569 NV\JR5FmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MontTWM2OD1yLkK1NVA3KM7:TR?= MnXuV2FPT0WU
HuO9 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwMk[3NVUh|ryP MVTTRW5ITVJ?
WM-115 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwMke3N|gh|ryP M4j6XXNCVkeHUh?=
CCRF-CEM NEfCfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7WNHRnUUN3ME2wMlM{PTJ7IN88US=> MV7TRW5ITVJ?
IST-SL1 NH;wPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTBwM{WzOFMh|ryP M3[5SnNCVkeHUh?=
BE-13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGO2cFBKSzVyPUCuN|Y1PTlizszN NVm1UZRVW0GQR1XS
COR-L88 NET3U4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrxTWM2OD1yLkO2OVQh|ryP MV;TRW5ITVJ?
DOHH-2 NILMT45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLGTZJJUUN3ME2wMlQyODJ|IN88US=> NHLFToVUSU6JRWK=
A704 NHT3cWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LXe2lEPTB;MD60NlY4KM7:TR?= MXHTRW5ITVJ?
KNS-81-FD NHrpSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnaPVVKSzVyPUCuOFQxOTdizszN M4HBSXNCVkeHUh?=
RPMI-8226 NYS2e4N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO3XYRLUUN3ME2wMlQ2PjV{IN88US=> NX3pXnNsW0GQR1XS
TGBC24TKB M13Se2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITsPFhKSzVyPUCuOFU4PzhizszN Ml\VV2FPT0WU
NCI-H1304 NWHx[G41T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofKTWM2OD1yLkS2NVU4KM7:TR?= NH\ocI1USU6JRWK=
MOLT-13 NFzSfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml[zTWM2OD1yLkS2OlE{KM7:TR?= NWHQZpJIW0GQR1XS
EW-22 NEfzUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTBwNE[2O|Eh|ryP M{nMSnNCVkeHUh?=
MS-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwNE[5N|Mh|ryP MX\TRW5ITVJ?
RMG-I NHrNNJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M131c2lEPTB;MD60PVQ3PCEQvF2= NX;EcmRuW0GQR1XS
NTERA-S-cl-D1 NGrpS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNUCwNVkh|ryP NV2yOVdtW0GQR1XS
NCI-H1048 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTBwNUC5OVMh|ryP MlnVV2FPT0WU
SW1417 M4\4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTxZ4pWUUN3ME2wMlU2PDN6IN88US=> M1fxSXNCVkeHUh?=
DB NIfET2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHXTGRKSzVyPUCuOVcxQCEQvF2= NXXtVpR7W0GQR1XS
MEG-01 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nqSmlEPTB;MD61PFMzKM7:TR?= NXi5fWhHW0GQR1XS
EW-13 M1LobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;BVWlEPTB;MD61PFM1OSEQvF2= Mn7TV2FPT0WU
LAMA-84 M3rhbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfsTWM2OD1yLkW5NlA4KM7:TR?= M3vISnNCVkeHUh?=
J-RT3-T3-5 M4\ES2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Wxc2lEPTB;MD62NFgxQCEQvF2= NF\sO3dUSU6JRWK=
MOLT-16 NUfsT5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnOTWM2OD1yLk[1NlY1KM7:TR?= M1vxXnNCVkeHUh?=
DU-4475 NYXyR4s2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33RVmlEPTB;MD62OVQzPyEQvF2= MV;TRW5ITVJ?
HAL-01 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXRdGw2UUN3ME2wMlczPTR7IN88US=> NWrtR5VlW0GQR1XS
RD NHjTNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjKTWM2OD1yLke1PFk6KM7:TR?= NIXve|hUSU6JRWK=
OAW-28 NULBW4FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17sW2lEPTB;MD63PFM4KM7:TR?= M3;xfnNCVkeHUh?=
HCC38 NY\MZY16T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nrS2lEPTB;MD64NFE6KM7:TR?= Ml3sV2FPT0WU
NMC-G1 NVjRd5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwOEGxNlEh|ryP NX;RW4xbW0GQR1XS
EW-16 NYfMeIVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV70S5BwUUN3ME2wMlgyOzJ6IN88US=> MUTTRW5ITVJ?
DU-145 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoD5TWM2OD1yLki5PVI{KM7:TR?= MonIV2FPT0WU
HPAF-II NUTIdXVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwOUK2Nlgh|ryP NX\GUmNnW0GQR1XS
A427 NH\3RWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\JdJFKSzVyPUCuPVMxOjJizszN M4nOVXNCVkeHUh?=
PA-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\HSYRKSzVyPUCuPVU3PDJizszN M{HUbHNCVkeHUh?=
OAW-42 MkLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLCNopKSzVyPUCuPVYyPDZizszN MkPMV2FPT0WU
L-428 NWT6WHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTFwMEGyOUDPxE1? NGLw[FRUSU6JRWK=
COLO-824 NH60U5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2LVVmlEPTB;MT6wNVcxQCEQvF2= NXXOZ|R[W0GQR1XS
P30-OHK NHj2ZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\xVHlJUUN3ME2xMlA1Pjh6IN88US=> MWnTRW5ITVJ?
NCI-H2170 NV\H[HVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHETWM2OD1zLkC2NlMh|ryP NVjH[4ZjW0GQR1XS
HCC2998 NGLRWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHxdIpbUUN3ME2xMlA4OTN3IN88US=> MoLwV2FPT0WU
NB14 MljGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfJTWM2OD1zLkGzO|Q5KM7:TR?= NIiyXXJUSU6JRWK=
TGBC1TKB NYLEc5ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3OzXGlEPTB;MT6xOFE2OiEQvF2= NHvGOIpUSU6JRWK=
KP-N-YS M1r1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jTTGlEPTB;MT6xOlI{PiEQvF2= M1;wSnNCVkeHUh?=
CAL-120 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmizTWM2OD1zLkG2OFI6KM7:TR?= MXHTRW5ITVJ?
SBC-1 NGfadpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rZcGlEPTB;MT6xPVA2OyEQvF2= MYDTRW5ITVJ?
C32 NHHYXJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXRXWlOUUN3ME2xMlE6ODh6IN88US=> MoPTV2FPT0WU
HCC2157 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrZfFBbUUN3ME2xMlE6PDl2IN88US=> MoftV2FPT0WU
COLO-792 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMkCwO|Eh|ryP MVHTRW5ITVJ?
ES7 NHW1TVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\zbHVKSzVyPUGuNlc6PTFizszN NGHTNZBUSU6JRWK=
HEL NI[xd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzWTWM2OD1zLkOxNFI6KM7:TR?= MoLKV2FPT0WU
ES4 M{Pp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G1WGlEPTB;MT6zOFk6QCEQvF2= NV;OUXFZW0GQR1XS
NCI-SNU-1 NFnFPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwM{[1OVUh|ryP NV\WZoRlW0GQR1XS
MDA-MB-415 NFHTflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDXPHlOUUN3ME2xMlM5QDVizszN MojsV2FPT0WU
NCI-H2342 M2qxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yxOWlEPTB;MT60NFI3QSEQvF2= MXvTRW5ITVJ?
NB69 M4HTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLLdWNKSzVyPUGuOFYzPzFizszN MmTXV2FPT0WU
D-247MG MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHwTWM2OD1zLkWxNVIzKM7:TR?= Ml\mV2FPT0WU
SCC-4 NX\IU|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nvfGlEPTB;MT61PVg5PyEQvF2= M{TwNXNCVkeHUh?=
HuH-7 NIm1fGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TQO2lEPTB;MT62O|I6OyEQvF2= NYf6cpdFW0GQR1XS
A388 M2m3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTFwNki3NlQh|ryP MlX3V2FPT0WU
Calu-3 Ml3DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTFwN{C2PVch|ryP M4S3XXNCVkeHUh?=
NCI-H1648 Mme2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLQTYJKSzVyPUGuO|E1OThizszN MVnTRW5ITVJ?
NCI-H2052 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTFwN{KyNFEh|ryP NV3mbJhQW0GQR1XS
Ramos-2G6-4C10 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTFwN{O2OVYh|ryP NYLiUVF1W0GQR1XS
DEL Mn;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXsRXpKSzVyPUGuO|Q3QTJizszN MmCzV2FPT0WU
SNU-423 NH7LNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jMbWlEPTB;MT63PFE2PyEQvF2= M{nOTHNCVkeHUh?=
COR-L23 NFLEPZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTFwN{m4O|Qh|ryP MYnTRW5ITVJ?
OMC-1 NFrlbWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTFwOE[wNVYh|ryP NEnpTZFUSU6JRWK=
EW-11 M2Hjbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ibGloUUN3ME2xMlk2PjV5IN88US=> MmPiV2FPT0WU
HSC-3 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u1SGlEPTB;MT65OlM3PSEQvF2= M1X0fHNCVkeHUh?=
MLMA NGTSRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTjRpIyUUN3ME2xMlk3Pjd5IN88US=> MUXTRW5ITVJ?
RCM-1 NUTCNG5mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFywcoZKSzVyPUKuNFA{QTlizszN MmXsV2FPT0WU
MFE-280 NWS2ephlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJwMEK4OFgh|ryP NU\YcGhsW0GQR1XS
ES8 NUPWPHVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\leYVrUUN3ME2yMlI2PDdzIN88US=> M4fK[HNCVkeHUh?=
TE-11 MnTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf4TWM2OD1{LkK5OFc{KM7:TR?= MWDTRW5ITVJ?
HuO-3N1 NIXp[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2X5cWlEPTB;Mj60PFc5KM7:TR?= MlHCV2FPT0WU
MHH-NB-11 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL0TWM2OD1{LkWxNVU5KM7:TR?= NYr3XIJ6W0GQR1XS
TGBC11TKB NUex[2x{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTmRoFbUUN3ME2yMlU4PjhzIN88US=> NGjwcVNUSU6JRWK=
HOP-92 NUPJdVNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTZTWM2OD1{LkW4O|Q{KM7:TR?= NFGzcXlUSU6JRWK=
IGR-1 M2nOSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVGxd2N1UUN3ME2yMlYzODN3IN88US=> NUSwcVdXW0GQR1XS
GOTO MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mke5TWM2OD1{Lk[1N|c4KM7:TR?= NIjYXIRUSU6JRWK=
NCI-H1650 M2HLd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3H5dGlEPTB;Mj63NlIyPSEQvF2= NVTubYhWW0GQR1XS
NCI-H1581 M170eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jvWWlEPTB;Mj63PVY5OSEQvF2= MkLIV2FPT0WU
NCI-H2405 M3zIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXw[HJoUUN3ME2yMlgzPzh{IN88US=> M4DGNHNCVkeHUh?=
U-118-MG MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTJwOU[0PVEh|ryP MV3TRW5ITVJ?
DoTc2-4510 NWnDRVNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf6TWM2OD1|LkCxOFE4KM7:TR?= NV;oU4R[W0GQR1XS
NCI-H596 Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEf0RXFKSzVyPUOuNFQ6QTdizszN MYPTRW5ITVJ?
MPP-89 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7nTWM2OD1|LkC1OlY3KM7:TR?= MXHTRW5ITVJ?
GCIY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LnO2lEPTB;Mz6yNFQ6OSEQvF2= Mlr1V2FPT0WU
SW626 M4nVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rsXGlEPTB;Mz6yOFU1OyEQvF2= MlW5V2FPT0WU
OCI-AML2 M3fzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\Xd2lKSzVyPUOuN|EzPzJizszN Ml;UV2FPT0WU
NBsusSR NF3XWm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDRTWM2OD1|LkO0PVM5KM7:TR?= MlTSV2FPT0WU
AN3-CA MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\VSmlEPTB;Mz60OFI{QCEQvF2= MmHZV2FPT0WU
EFM-19 M1;nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LqRmlEPTB;Mz60PFM{QSEQvF2= NUfURo05W0GQR1XS
RVH-421 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNwNU[4O|ch|ryP NFzJbphUSU6JRWK=
5637 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlyyTWM2OD1|Lk[xNVA{KM7:TR?= MlXOV2FPT0WU
PANC-08-13 NVzPUoMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LvS2lEPTB;Mz62N|Q4OiEQvF2= NHnMV3VUSU6JRWK=
H9 M2e4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGqzRYRKSzVyPUOuOlcyPDRizszN MlO1V2FPT0WU
KARPAS-299 NHX1fmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fpVGlEPTB;Mz62O|M3OSEQvF2= NXrWc2ZJW0GQR1XS
TE-5 NWrxc|djT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXX6NmlUUUN3ME2zMlcxPzB7IN88US=> MYHTRW5ITVJ?
NOS-1 NUnWSYYxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLqWHJzUUN3ME2zMlc6QDN2IN88US=> NGLZdItUSU6JRWK=
HH MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTNwOEO4Olgh|ryP MW\TRW5ITVJ?
769-P M{fX[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moj4TWM2OD1|Lki5OVEh|ryP MUjTRW5ITVJ?
CHP-212 NHXzXnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorhTWM2OD1|LkmyOVQ6KM7:TR?= MU\TRW5ITVJ?
NCI-H82 M2n3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrrcWd1UUN3ME2zMlk2QTN4IN88US=> NIXCTpBUSU6JRWK=
Mo-T NGD5V4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvvWoNKSzVyPUSuNFQ{OTJizszN NYLZTlFDW0GQR1XS
BB65-RCC MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT3TWM2OD12LkC0N|k6KM7:TR?= NV31fo9KW0GQR1XS
SW1990 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTRwMEW5NFgh|ryP M2DHNnNCVkeHUh?=
LK-2 NVP6XpVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnezTWM2OD12LkGxNlk{KM7:TR?= MlL4V2FPT0WU
ES5 NH3L[ZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTRwMUO5PFUh|ryP M2HFR3NCVkeHUh?=
JVM-3 MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;0R2lEPTB;ND6xPFIzOiEQvF2= MVLTRW5ITVJ?
RPMI-7951 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTRwMkK0NVMh|ryP MVjTRW5ITVJ?
Calu-6 NGLO[XdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjZNGc{UUN3ME20MlI4QDhzIN88US=> MlzGV2FPT0WU
LC-2-ad NF;5R25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLaSm1KSzVyPUSuNlk2PjhizszN NEXRTI1USU6JRWK=
SW954 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXvWY1KSzVyPUSuNlk3PiEQvF2= M{LwWHNCVkeHUh?=
H-EMC-SS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvpTWM2OD12LkOxPFMyKM7:TR?= MX\TRW5ITVJ?
ES3 M4rjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTRwM{W0OFEh|ryP NVfxPGM{W0GQR1XS
no-11 MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PS[WlEPTB;ND6zOVU2PCEQvF2= MoDCV2FPT0WU
LAN-6 NEXIPZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v1emlEPTB;ND60OVE5QSEQvF2= M2n6VXNCVkeHUh?=
FTC-133 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTRwNUO5OUDPxE1? NHSxPXZUSU6JRWK=
8505C NFnOTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7n[mlzUUN3ME20MlU1OjNizszN MVrTRW5ITVJ?
SW620 NF7EVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\pTWM2OD12LkW3NFU4KM7:TR?= M{XiNXNCVkeHUh?=
BCPAP M{XYeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDIdoRVUUN3ME20MlY{PDhzIN88US=> M2DmZ3NCVkeHUh?=
SK-LU-1 NF6ycnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkD0TWM2OD12Lk[2NFg6KM7:TR?= MlnKV2FPT0WU
NCI-H1623 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtZ5BKSzVyPUSuO|AzOjhizszN MXzTRW5ITVJ?
C2BBe1 NVPHNFJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG2XFVKSzVyPUSuO|QxODhizszN M{TaRnNCVkeHUh?=
GP5d NES2THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTRwN{izPFgh|ryP Ml7IV2FPT0WU
NB6 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYflOYJOUUN3ME20Mlg3OjB2IN88US=> NUTN[mliW0GQR1XS
MDA-MB-157 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjvcnRKSzVyPUSuPFg4PiEQvF2= NWLK[o5VW0GQR1XS
UMC-11 NUfuRpo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHZXoVKSzVyPUSuPFg6PjRizszN NITDblRUSU6JRWK=
HCC1419 NWnVUYRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXmS|dKSzVyPUSuPVAxPjNizszN MVPTRW5ITVJ?
NCI-H2029 M1G3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXuTWM2OD12Lkm0NVg2KM7:TR?= NUfxNWVLW0GQR1XS
LXF-289 NGfyeFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTWY1XUUN3ME21MlA{PzF7IN88US=> NXr4S4J[W0GQR1XS
KINGS-1 NVzaVIQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnmwTWM2OD13LkC3O|Q1KM7:TR?= M3WzXnNCVkeHUh?=
HD-MY-Z NYjoUpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml61TWM2OD13LkKzPVY6KM7:TR?= NUXxUXZQW0GQR1XS
ESS-1 NXLoe4Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rQR2lEPTB;NT6yOVU6PyEQvF2= NGHXeoNUSU6JRWK=
GI-1 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHMZZlKSzVyPUWuNlc6OjZizszN MoX0V2FPT0WU
RPMI-2650 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Dd5NKSzVyPUWuN|YyPiEQvF2= NWX5V5gxW0GQR1XS
IA-LM NWHIUYZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTVwM{m4O|Eh|ryP MoL6V2FPT0WU
KP-4 MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXxToVKSzVyPUWuOFY{OzRizszN NWnoNlg4W0GQR1XS
G-402 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2WYlKSzVyPUWuOVE5PjVizszN NWDTWHZwW0GQR1XS
OS-RC-2 NEHQeI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTVwNUK2NFQh|ryP M1SyXnNCVkeHUh?=
NCI-H1155 NFzjdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfUe2pxUUN3ME21MlU1QTV3IN88US=> NUGwbYs{W0GQR1XS
OE19 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HhfWlEPTB;NT62PFYzPCEQvF2= MUHTRW5ITVJ?
U-2-OS NETLXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrKUGdjUUN3ME21Mlg6ODF|IN88US=> MoTKV2FPT0WU
SCC-15 M3TkN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLqN|dpUUN3ME21Mlk{PjZ{IN88US=> MnHLV2FPT0WU
NCI-H630 NUjWZ|JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXzcXJKSzVyPUWuPVk1ODRizszN NIjwZVNUSU6JRWK=
PFSK-1 M1fWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rsO2lEPTB;Nj6wOVI2QSEQvF2= MmD1V2FPT0WU
NCI-H1770 NU\JVW1bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Thb2lEPTB;Nj6yNFg4PCEQvF2= NYm4ZlFTW0GQR1XS
SK-MEL-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G2SGlEPTB;Nj60NlkyPSEQvF2= NU\WfJRoW0GQR1XS
LB1047-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTZwNEe2NlUh|ryP M2XFRnNCVkeHUh?=
NCI-H446 M1L2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTZwNkK5NlUh|ryP NGn0Nm1USU6JRWK=
SW780 M4X5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDYWWxNUUN3ME22MlcxOTh3IN88US=> NVe5RoRPW0GQR1XS
NEC8 NH;NVlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3WxUWlEPTB;Nj63OlY{KM7:TR?= NWPoUoNPW0GQR1XS
NOMO-1 NXnGcolqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnSUVhKSzVyPU[uO|gyOTFizszN NIXYNHZUSU6JRWK=
COLO-668 NF7wS2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoSwTWM2OD14Lki0N|g4KM7:TR?= MVPTRW5ITVJ?
MC116 NFn5fG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTZwOUO4PVch|ryP M2jXbXNCVkeHUh?=
HCC1937 NF;RNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrSPG9DUUN3ME22Mlk6OjVzIN88US=> NVrYNHpbW0GQR1XS
NCI-N87 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTaTWM2OD15LkG5Nlk{KM7:TR?= M3f3bXNCVkeHUh?=
COLO-320-HSR M3HQbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPiTWM2OD15LkKyO|M5KM7:TR?= MYXTRW5ITVJ?
HCC1806 NVK5eJR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T3Z2lEPTB;Nz6yOlA1PCEQvF2= M2D1R3NCVkeHUh?=
OVCAR-3 NGfHfJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkeyTWM2OD15LkOzNFM5KM7:TR?= MVLTRW5ITVJ?
NUGC-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLHTWM2OD15LkO5Olk1KM7:TR?= NUPLXZBRW0GQR1XS
SW1783 NIH2ZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\K[2lEPTB;Nz60N|E4PSEQvF2= M1f0eHNCVkeHUh?=
GCT MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf6UWlKSzVyPUeuOVY6ODZizszN MoXMV2FPT0WU
NCI-H2126 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17WO2lEPTB;Nz63N|YzPSEQvF2= MUnTRW5ITVJ?
MEL-HO M3:wU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\FTWM2OD15Lke3NFU1KM7:TR?= NHvKbWJUSU6JRWK=
CAPAN-1 NXjsTIlnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwN{ezOVch|ryP M3PEXnNCVkeHUh?=
SW756 NH7qZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmy[IMxUUN3ME23Mlc5OzN|IN88US=> NUHzdlNYW0GQR1XS
SKG-IIIa NUm1bGdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4[ydGlEPTB;Nz64NVg6OiEQvF2= MUjTRW5ITVJ?
HCE-T M{nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHBe|hbUUN3ME23Mlg4Pzh|IN88US=> MmLGV2FPT0WU
Ca-Ski MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUmzdIJKUUN3ME23Mlk6Ozh|IN88US=> MlroV2FPT0WU
COLO-684 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DYO2lEPTB;OD6wNVgyQCEQvF2= NEnCfWtUSU6JRWK=
KYSE-70 M3n5Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRThwMEe3Nlkh|ryP MmDIV2FPT0WU
TI-73 M4XXUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q0dmlEPTB;OD6yOVg2OSEQvF2= MX7TRW5ITVJ?
BT-20 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRThwMk[wOVIh|ryP MlXTV2FPT0WU
MHH-ES-1 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrqTGtSUUN3ME24MlUyQDN2IN88US=> MVzTRW5ITVJ?
TE-12 NHX1OIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\tZmlEPTB;OD61PVk{OSEQvF2= NIHuO2NUSU6JRWK=
YH-13 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwNkGwNFgh|ryP MXHTRW5ITVJ?
SF126 NGnoOVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUToe3NTUUN3ME24Mlg{QDZ3IN88US=> M1XlZ3NCVkeHUh?=
J82 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRThwOUCwN|gh|ryP NG\kPWxUSU6JRWK=
RCC10RGB MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRThwOUm1OlEh|ryP NUTs[YsxW0GQR1XS
SK-UT-1 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vENWlEPTB;OT6wOFk1PSEQvF2= NW\LWJd7W0GQR1XS
LB2241-RCC MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTlwMUmxN|ch|ryP NVvt[o5xW0GQR1XS
LB996-RCC M3zMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX:zZXVNUUN3ME25MlE6QDlizszN Mmr4V2FPT0WU
EPLC-272H MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LLdGlEPTB;OT6zO|Y2PyEQvF2= MUDTRW5ITVJ?
CTV-1 NWW0[HBST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nWVmlEPTB;OT61OlU{OiEQvF2= MlXJV2FPT0WU
HSC-2 M2TTSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3EVm1TUUN3ME25MlU4PTVizszN M{LuXnNCVkeHUh?=
SK-MEL-28 NEDFVFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz2TWM2OD17Lk[xPFk{KM7:TR?= MVjTRW5ITVJ?
MMAC-SF M1LyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHDTWM2OD17Lk[4O|Uh|ryP NHmxb29USU6JRWK=
CP50-MEL-B NHHMNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTlwN{W3PFIh|ryP Mlz3V2FPT0WU
HT-1080 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jCOmlEPTB;OT63O|c{QSEQvF2= MYXTRW5ITVJ?
HEC-1 Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXOzPHhbUUN3ME2xNE4{OzV{IN88US=> NFPrPWRUSU6JRWK=
AGS M{XFSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvNZnBKSzVyPUGwMlM4PCEQvF2= M2rI[XNCVkeHUh?=
GAMG MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPoTWM2OD1zMD61NVYzKM7:TR?= M3v0XnNCVkeHUh?=
SW48 NIr2TIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPwboJDUUN3ME2xNE42OTh7IN88US=> NV;yPYhGW0GQR1XS
U031 NED3VZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqzOWhnUUN3ME2xNE42QTB6IN88US=> M2DlOXNCVkeHUh?=
OVCAR-5 M1;4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWL6dpFEUUN3ME2xNE43PDJ7IN88US=> NYK5WJZsW0GQR1XS
SF295 NYfwZ5pUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYToS2xHUUN3ME2xNE43PzB2IN88US=> NXHEPIVXW0GQR1XS
BHT-101 MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfLTWM2OD1zMD63NVc4KM7:TR?= M1vTOHNCVkeHUh?=
VMRC-RCZ M13q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHG4bIpKSzVyPUGxMlMzODFizszN MXPTRW5ITVJ?
ACHN MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTFzLkSyNVEh|ryP MXHTRW5ITVJ?
NCI-H526 NWnhXZI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTY[5ZsUUN3ME2xNU42ODR|IN88US=> NH7XWJRUSU6JRWK=
MN-60 NEDMRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFzLkWzPUDPxE1? M1fHVXNCVkeHUh?=
NCI-H2291 NXTTPY51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzZOY1KSzVyPUGxMlU1PjZizszN NI[1SlNUSU6JRWK=
SCC-25 NGHYZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\jTWM2OD1zMT63OVU3KM7:TR?= NYT3[JlWW0GQR1XS
SK-MEL-2 NUW2NldCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFzLke2N|ch|ryP MVPTRW5ITVJ?
SN12C NX3aPGRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlyzTWM2OD1zMT65N|U2KM7:TR?= NVT4SndWW0GQR1XS
NCI-H69 NI\v[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL0TWM2OD1zMj60NlM1KM7:TR?= NITOTXhUSU6JRWK=
ME-180 NYrrcJI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\0TWM2OD1zMj63NFU1KM7:TR?= NXq2bmM2W0GQR1XS
MC-IXC NWLFbXo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;6OG5KSzVyPUGyMlc2OThizszN MY\TRW5ITVJ?
NCI-H2347 NHz6cm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HOW2lEPTB;MUKuO|YyPCEQvF2= MnXQV2FPT0WU
M059J MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDq[2xKSzVyPUGyMlc4OjdizszN MY\TRW5ITVJ?
A2058 NVTwZ29jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\PZWlEPTB;MUKuPFY5OSEQvF2= MljuV2FPT0WU
VA-ES-BJ MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2C1[WlEPTB;MUKuPFc5PSEQvF2= M3nmVXNCVkeHUh?=
Ca9-22 NHnPXGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLVdHVKSzVyPUGyMlk1PTFizszN NUHEcJZoW0GQR1XS
KNS-42 M1zMRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF{Lkm5PFQh|ryP MXnTRW5ITVJ?
LoVo NXTNNFUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfXTWM2OD1zMz6yN|E{KM7:TR?= MWrTRW5ITVJ?
AM-38 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LFWGlEPTB;MUOuNlU3PiEQvF2= NGfHNItUSU6JRWK=
NB5 MlXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rsTmlEPTB;MUOuN|c2OiEQvF2= NH:yWY1USU6JRWK=
L-363 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;QUmlEPTB;MUOuOFA{OyEQvF2= MljJV2FPT0WU
SK-MEL-30 MorSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H0WWlEPTB;MUSuNFY1PSEQvF2= NHjKRZFUSU6JRWK=
NCI-H1563 M4TrV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTjUpJKSzVyPUG0MlYxOzlizszN MmLkV2FPT0WU
NCI-H2228 NYL3cJF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fiT2lEPTB;MUSuOlA4PyEQvF2= NWDJ[nd2W0GQR1XS
MFM-223 NISxe2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTlXndUUUN3ME2xOU4yQDF|IN88US=> MVXTRW5ITVJ?
LB831-BLC NHeyNYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofWTWM2OD1zNT6yO|Y4KM7:TR?= NYGyWoliW0GQR1XS
SW872 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHCdGRDUUN3ME2xOU4{ODh4IN88US=> MnS0V2FPT0WU
NCI-H522 M1vNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHP5N4VKSzVyPUG1MlM{ODZizszN NIDB[VFUSU6JRWK=
EW-1 M3PsOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfNTWM2OD1zNT61OFYzKM7:TR?= MXvTRW5ITVJ?
HN NE[zZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHrWndKUUN3ME2xOU42QTR{IN88US=> NH3MTFBUSU6JRWK=
SW837 NVHBZnRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3MTWM2OD1zNT63PFQ4KM7:TR?= M{Ls[3NCVkeHUh?=
SCC-9 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjvTWM2OD1zNT64NVE1KM7:TR?= MnrTV2FPT0WU
MKN7 NV\GXndKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPFTWM2OD1zNT65O|MzKM7:TR?= M2D5fHNCVkeHUh?=
KYSE-410 MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTF4LkW5NUDPxE1? MnLnV2FPT0WU
SK-N-DZ NV30Oo9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rNSGlEPTB;MU[uOlEyPiEQvF2= MmW5V2FPT0WU
COR-L105 NXXXXI94T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC4THFKSzVyPUG2MlY2OjhizszN MULTRW5ITVJ?
LB2518-MEL MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXXcHczUUN3ME2xOk45Ozh7IN88US=> MV;TRW5ITVJ?
OVCAR-4 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7LcopjUUN3ME2xOk45QDZ{IN88US=> NX\ZTYFGW0GQR1XS
TK10 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4Lkm0O|Mh|ryP MW\TRW5ITVJ?
KNS-62 M{fUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTF4Lkm3O|ch|ryP NUXGVXpzW0GQR1XS
RPMI-8866 NHjjV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7UTWM2OD1zNz6xO|MzKM7:TR?= NVnYZo5vW0GQR1XS
HuP-T4 NFP5[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPJTWM2OD1zNz6yOFk2KM7:TR?= M1Tz[HNCVkeHUh?=
CGTH-W-1 NHy3PXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTF5LkWyNVkh|ryP MlHSV2FPT0WU
T-24 Ml3hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XSWmlEPTB;MUeuOVM1PyEQvF2= MkDSV2FPT0WU
HT-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDXTWM2OD1zNz61PVE1KM7:TR?= MWTTRW5ITVJ?
KS-1 MnGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3u5cWlEPTB;MUeuOlc{KM7:TR?= NUPJcYJ{W0GQR1XS
NCI-H1792 NXTneFRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\lUmlEPTB;MUeuO|k5KM7:TR?= M3WwUHNCVkeHUh?=
ABC-1 M{XIZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTF5LkixOFEh|ryP MkX5V2FPT0WU
BPH-1 MmPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;XTWM2OD1zOD6xOlg2KM7:TR?= M3LnU3NCVkeHUh?=
A431 NEPrfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTEbW1[UUN3ME2xPE41OTJ5IN88US=> MnO5V2FPT0WU
T98G NHT4RnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkH2TWM2OD1zOD61NVU4KM7:TR?= NHq2dXpUSU6JRWK=
BHY MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTF6Lki2PUDPxE1? NInuc|hUSU6JRWK=
Capan-2 NGnqTYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXficlNYUUN3ME2xPE46ODd6IN88US=> M{TLUnNCVkeHUh?=
MDA-MB-175-VII M1e5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH2TYN{UUN3ME2xPE46OjB7IN88US=> M1O3N3NCVkeHUh?=
CAL-27 M4TINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETZdmdKSzVyPUG5MlA1QDdizszN NHTCdWZUSU6JRWK=
AsPC-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI[y[Y9KSzVyPUG5Mlg3PTdizszN MXzTRW5ITVJ?
KU812 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fkVWlEPTB;MUmuPVU4OyEQvF2= NEfHW|BUSU6JRWK=
NCI-H441 M3LLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJyLkCwNUDPxE1? NVHYZ5g2W0GQR1XS
Mewo NYDBN5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFv6bnlKSzVyPUKwMlEzQDhizszN MVHTRW5ITVJ?
SK-MEL-24 M{nLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTJyLkG0O|ch|ryP M3PtW3NCVkeHUh?=
NCI-H727 NHzQT2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HqV2lEPTB;MkCuNlcxPCEQvF2= MlfYV2FPT0WU
EKVX NH\RXWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJyLk[wOkDPxE1? NFrDbnhUSU6JRWK=
RT-112 Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2m1N2lEPTB;MkCuOlEzOiEQvF2= NHTYcIdUSU6JRWK=
CAMA-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[zTWM2OD1{MD65PFA{KM7:TR?= MmniV2FPT0WU
SW900 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TxdGlEPTB;MkGuNFE1QSEQvF2= NXj2eHF4W0GQR1XS
NCI-H23 M1TTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPpT5hxUUN3ME2yNU4yOjd5IN88US=> MnjOV2FPT0WU
SK-PN-DW NWnzfY9WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHvdJlKSzVyPUKxMlE3PDlizszN MWfTRW5ITVJ?
BB30-HNC M1nHSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jxZmlEPTB;MkGuNlc1PSEQvF2= NXH2fpUyW0GQR1XS
VM-CUB-1 M{mwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPa[lZKSzVyPUKxMlM2OzZizszN Mk\OV2FPT0WU
IST-MEL1 MlG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1raWWlEPTB;MkGuN|Y6OiEQvF2= NHX0c2FUSU6JRWK=
CTB-1 Mnr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LweWlEPTB;MkGuOFc2PSEQvF2= NGniS41USU6JRWK=
LCLC-103H MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7oT4ozUUN3ME2yNk4yPTh{IN88US=> M3jCUXNCVkeHUh?=
PANC-03-27 NFLN[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ{LkWxOlkh|ryP NIrYUYxUSU6JRWK=
HTC-C3 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfHcY1EUUN3ME2yNk42PTV3IN88US=> M4\NUXNCVkeHUh?=
TE-8 M3\RSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHhTWM2OD1{Mz6yOVY2KM7:TR?= Ml3RV2FPT0WU
NCI-H292 NXrifFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTkTWM2OD1{NT6zOVM3KM7:TR?= MoX6V2FPT0WU
COLO-680N MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j6b2lEPTB;MkWuOlMzQSEQvF2= NYO5NohRW0GQR1XS
KYSE-520 M1:3Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWLrSXU3UUN3ME2yOU43PDRizszN NHzP[YJUSU6JRWK=
NB10 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDiTWM2OD1{Nj6zNVE4KM7:TR?= NH:5ZllUSU6JRWK=
NCI-H661 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkG4TWM2OD1{Nj60O|E{KM7:TR?= NIDINZZUSU6JRWK=
GMS-10 NVLobXpnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTJ4Lki2N|gh|ryP M{DHfHNCVkeHUh?=
NCI-H2122 M1rqNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDQPYJ3UUN3ME2yOk46QTl6IN88US=> MVHTRW5ITVJ?
OVCAR-8 Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;iTWM2OD1{Nz6wOlM5KM7:TR?= NEm1[ZNUSU6JRWK=
DJM-1 M1nIXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;UOWlEPTB;MkeuNVQ2PCEQvF2= NY\RdYpMW0GQR1XS
UACC-893 Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfa[Y9KUUN3ME2yO{46QDd6IN88US=> M3nHOXNCVkeHUh?=
C8166 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj0TWM2OD1{OD62PVM5KM7:TR?= M1;pRXNCVkeHUh?=
NCI-H1693 NEW3d|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTJ6Lk[5O|Uh|ryP MlS0V2FPT0WU
TYK-nu M{D1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33xVmlEPTB;M{CuNFM1PSEQvF2= MUDTRW5ITVJ?
SW1710 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzMT|VKSzVyPUOwMlEzPiEQvF2= MUDTRW5ITVJ?
A375 NXG2eoxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHRRWwzUUN3ME2zNE4{OjR|IN88US=> MorVV2FPT0WU
HMV-II NEfuPHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3nBcWlEPTB;M{GuN|U6OiEQvF2= MkHFV2FPT0WU
NCI-H2087 NV60RYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDSSotLUUN3ME2zNU43OzV{IN88US=> NH;2eZVUSU6JRWK=
CAL-54 Mo\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrRTmVKSzVyPUOxMlczPDFizszN NXLFRnF5W0GQR1XS
HCC70 NEPMdJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rudWlEPTB;M{KuNVM5PyEQvF2= MWjTRW5ITVJ?
ES1 M36y[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnIeXdnUUN3ME2zNk4{ODZ{IN88US=> M3naW3NCVkeHUh?=
NCI-H1355 MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PEWGlEPTB;M{OuNlA1KM7:TR?= NU\QeWVDW0GQR1XS
CFPAC-1 MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN|LkKzN|Ih|ryP MkOzV2FPT0WU
MKN28 NWW1b2RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTN|LkO4NFkh|ryP NHu4TGlUSU6JRWK=
HDLM-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7aXFFOUUN3ME2zN{43QTNzIN88US=> MljJV2FPT0WU
PANC-10-05 NEnH[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzYXoNKSzVyPUO0MlExOTRizszN MYDTRW5ITVJ?
SAS MknRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml35TWM2OD1|ND60OVY2KM7:TR?= MlfjV2FPT0WU
HCC1395 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPZVW5KSzVyPUO0MlcyQDZizszN MlLGV2FPT0WU
8305C M2PQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnETWM2OD1|NT64OFE2KM7:TR?= M13xWHNCVkeHUh?=
KM12 M2fEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILIWmRKSzVyPUO2Mlc2PDdizszN MVXTRW5ITVJ?
SW1116 NYjKOYUzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTN5LkW5PVIh|ryP MkjmV2FPT0WU
SK-MEL-1 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTN6LkOzPFkh|ryP MoT2V2FPT0WU
HCC2218 NH[ye5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTN6Lk[1NVkh|ryP M3vvRnNCVkeHUh?=
T84 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTN6Lke0NFkh|ryP MYnTRW5ITVJ?
ETK-1 M3G5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TNOmlEPTB;M{muNFIzKM7:TR?= NFLaWVFUSU6JRWK=
COLO-800 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWezZY56UUN3ME2zPU4{QDZ6IN88US=> Mkf0V2FPT0WU
CAL-12T M2n5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTN7LkWyPFEh|ryP MmTMV2FPT0WU
ACN NIDjZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkC4TWM2OD12MD60PVEyKM7:TR?= MmnVV2FPT0WU
SJSA-1 MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjTNINFUUN3ME20NU4yPTl4IN88US=> MmrmV2FPT0WU
PSN1 M1j4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDPcJlKSzVyPUSxMlE4PDlizszN NYrWcmhKW0GQR1XS
D-566MG NUPZfXprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTRzLkKwPFYh|ryP M1LYTHNCVkeHUh?=
EGI-1 NVTNcVBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTR{LkSyPEDPxE1? M1jwPHNCVkeHUh?=
A204 M3zqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTR{Lk[zPFgh|ryP MYXTRW5ITVJ?
Saos-2 NEXRN4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXpUmFKSzVyPUSyMlg{PjlizszN NIfIRmNUSU6JRWK=
SNU-C2B M3nrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjobFJKSzVyPUSzMlY5PzhizszN M33SV3NCVkeHUh?=
HLE MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HnWWlEPTB;NESuNFg2PiEQvF2= NETYSIRUSU6JRWK=
SW1463 M3vnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPM[mFKSzVyPUS0Mlk6PzFizszN Moj0V2FPT0WU
DSH1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TYOmlEPTB;NEWuNFA{OyEQvF2= NWfl[G5HW0GQR1XS
MCF7 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HFdmlEPTB;NEWuOVA2OSEQvF2= MWDTRW5ITVJ?
K5 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6zcpplUUN3ME20OU46PDB3IN88US=> NVjYWnlSW0GQR1XS
NCI-H358 NW\pRYVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rDS2lEPTB;NEeuNlE2KM7:TR?= MoHBV2FPT0WU
NCI-H2030 NVfC[JNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DSXGlEPTB;NEeuNlM4PCEQvF2= NWLqToluW0GQR1XS
SW948 NVHablV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTR5LkS2OEDPxE1? M{TpT3NCVkeHUh?=
BALL-1 NWrVUpB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LhTWlEPTB;NEeuOlE3QCEQvF2= NIezfYRUSU6JRWK=
TE-9 NFTTeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTQZ|ZKSzVyPUS3Mlk2QDFizszN MV7TRW5ITVJ?
SK-N-FI NUTKV3k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHK0UXZKSzVyPUS4MlA{PThizszN MYPTRW5ITVJ?
KALS-1 M2fIWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fROmlEPTB;NEiuNVI5QSEQvF2= MVXTRW5ITVJ?
HO-1-N-1 NGX6OJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPKVlB[UUN3ME20PE44PDR3IN88US=> MXfTRW5ITVJ?
NCI-H2452 NF3ZeIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTDeoNKSzVyPUS5MlEyPTJizszN M17IVnNCVkeHUh?=
OC-314 MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLMTWM2OD12OT62PFM1KM7:TR?= NFjXdGRUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5% DMSO+corn oil
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID